Copenhagen, Denmark; November 3, 2005 – Genmab A/S (CSE: GEN) announced today that a patent has been issued for HuMax®-HepC by the US Patent and Trademark Office.   HuMax-HepC is a fully human antibody currently in pre-clinical development to prevent reinfection with the Hepatitis C Virus (HCV) after liver transplantation.  HuMax-HepC binds to a common site on diverse strains of the virus. In pre-clinical studies, the antibody prevented the HCV from attaching to susceptible cells.

 

“The issuance of the HuMax-HepC patent marks another important milestone in building our business,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.  “The patent provides broad protection over this unique antibody and gives us a potential edge over other biotech companies competing in the same arena.”